Evelyn Traina

Dr. Evelyn Traina

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
ADAmanda Dantas-Silva
Amanda Dantas-Silva
FSFernanda Surita
Fernanda Surita
RSRenato Souza
Renato Souza
LRLeila Rocha
Leila Rocha
JGJosé Paulo Guida
José Paulo Guida
MCMaria Laura Costa
Maria Laura Costa
Objective To evaluate the impact of the race (Black versus non-Black) on maternal and perinatal outcomes of pregnant women with COVID-19 in Brazil. Methods This is a subanalysis of REBRACO, a Brazilian multicenter cohort study designed to evaluate the impact of COVID-19 on pregnant women. From February 2020 until February 2021, 15 maternity hospitals in Brazil collected data on women with respiratory symptoms. We selected all women with a positive test for COVID-19; then, we divided them into two groups: Black and non-Black women. Finally, we compared, between groups, sociodemographic, maternal, and perinatal outcomes. We obtained the frequency of events in each group and compared them using X2 test; p-values < 0.05 were considered significant. We also estimated the odds ratio (OR) and confidence intervals (CI). Results 729 symptomatic women were included in the study; of those, 285 were positive for COVID-19, 120 (42.1%) were Black, and 165 (57.9%) were non-Black. Black women had worse education (p = 0.037). The timing of access to the health system was similar between both groups, with 26.3% being included with seven or more days of symptoms. Severe acute respiratory syndrome (OR 2.22 CI 1.17–4.21), intensive care unit admission (OR 2.00 CI 1.07–3.74), and desaturation at admission (OR 3.72 CI 1.41–9.84) were more likely to occur among Black women. Maternal death was higher among Black women (7.8% vs. 2.6%, p = 0.048). Perinatal outcomes were similar between both groups. Conclusion Brazilian Black women were more likely to die due to the consequences of COVID-19.

Verified
Journal Article
Open access
PDF file
LMLivian Cássia De Melo
Livian Cássia De Melo
Marina RugnaMarina Rugna
Marina Rugna
TDTalita Almeida Durães
Talita Almeida Durães
SPStefany Silva Pereira
Stefany Silva Pereira
GCGustavo Yano Callado
Gustavo Yano Callado
Roberta GraneseRoberta Granese
Roberta Granese
Congenital Rubella Syndrome (CRS) results from maternal infection with the rubella virus during pregnancy, particularly in the first trimester, when the risk of vertical transmission and severe fetal damage is highest. CRS is characterized by a broad spectrum of congenital anomalies, including sensorineural hearing loss, congenital heart defects, cataracts, neurodevelopmental delay, and behavioral disorders. Despite the absence of specific antiviral therapies, active immunization remains the only effective strategy to prevent rubella infection and its congenital consequences. Global immunization efforts, particularly in the Americas, have led to the elimination of rubella and CRS in several countries. However, challenges persist in the post-elimination era, including declining vaccine coverage, vaccine hesitancy, and setbacks caused by the COVID-19 pandemic. Diagnosis relies on maternal serology, fetal imaging, postnatal antibody testing, and molecular techniques. Management requires long-term, multidisciplinary follow-up due to the complex and lifelong sequelae affecting sensory, motor, and cognitive development. This review highlights the clinical, epidemiological, and pathophysiological aspects of CRS, while emphasizing the urgent need to maintain high vaccination coverage and strengthen surveillance systems. Sustained public health commitment is essential to prevent the reemergence of rubella and protect future generations from this preventable syndrome.

21 October 2024 in Journal of Perinatal Medicine
Verified
Journal Article
Open access
MVMarlene Carvalho Teixeira Valença
Marlene Carvalho Teixeira Valença
MFMarcelo Santucci França
Marcelo Santucci França
RMRosiane Mattar
Rosiane Mattar
PDPatricia Dualib
Patricia Dualib
VSVictor Hugo Saucedo Sanchez
Victor Hugo Saucedo Sanchez
ETEvelyn Traina
Evelyn Traina
Objectives: To compare the effectiveness of outpatient nutritional guidance supplemented by digital media with exclusively standard outpatient nutritional guidance in pregnant women with gestational diabetes mellitus (GDM). Methods: This was a randomized, patient-blinded clinical trial conducted at the Diabetes and Pregnancy outpatient clinic from February 2021 to January 2023. Pregnant women with GDM were randomly allocated into two groups: the control group received exclusively outpatient nutritional guidance, and the Intervention Group received outpatient nutritional guidance along with reminders via WhatsApp. Dietary intake (calories, carbohydrates, lipids, proteins, and fibers) was evaluated using 24 h dietary recalls. Glycemic control and the need for pharmacological treatment were also assessed. Results: A total of 81 women were included, 34 allocated to the control group, and 47 to the intervention group. Patients were followed for a period of 4–8 weeks. Significant differences were observed in some points of glycemic control between the two groups over the follow-up period. There were no statistical differences in pharmacological therapy (p=0.498); 188 24 h dietary recall were conducted in the control group and 290 in the intervention group. A statistically significant increase in lipid intake was observed in the intervention group over the follow-up period compared to the control group (p<0.001). No changes in calorie intake, other macronutrients, or fiber consumption were noted. Conclusions: Glycemic control was significantly improved with the addition of frequent text reminders about dietary choices, and a significant increase in lipid intake was seen in all women, more so in the reminder group.

Verified
Journal Article
Open access
PDF file
ASAna Luiza Soares dos Santos
Ana Luiza Soares dos Santos
BRBeatriz Bussi Rosolen
Beatriz Bussi Rosolen
FFFernanda Curvelo Ferreira
Fernanda Curvelo Ferreira
ICIsabella Samões Chiancone
Isabella Samões Chiancone
SPStefany Silva Pereira
Stefany Silva Pereira
Edward Araujo JúniorEdward Araujo Júnior
Edward Araujo Júnior
Zika virus (ZIKV) is a mosquito-borne flavivirus of the family Flaviviridae. The association between ZIKV and microcephaly was first described in Brazil in 2015. The risk of vertical transmission occurs in pregnant women with or without symptoms, and the risk of malformation appears to be worse when infection occurs in the first and second trimesters of pregnancy. The rate of vertical transmission varies from 26 to 65%, and not all fetuses develop malformations. The incidence of malformations resulting from transmission is uncertain, ranging from 6–8% in the US to 40% in Brazil. Congenital ZIKV syndrome is a set of clinical manifestations that can affect the fetus of a mother infected with ZIKV. The manifestations are broad and nonspecific, including microcephaly, subcortical calcifications, ocular changes, congenital contractures, early hypertension, and pyramidal and extrapyramidal signs. Other findings such as growth restriction and fetal miscarriage/death may also occur. Our aim in this article is to review the literature on mosquito transmission, clinical presentation, serologic diagnosis, intrauterine transmission, pre- and postnatal imaging diagnostic findings, and short- and long-term follow-up.

5 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SPStefany Silva Pereira
Stefany Silva Pereira
ABAntonio Braga
Antonio Braga
BRBeatriz Bussi Rosolen
Beatriz Bussi Rosolen
TDTalita Almeida Durães
Talita Almeida Durães
MSMarcela Fermoselle de Vita Silva
Marcela Fermoselle de Vita Silva
Roberta GraneseRoberta Granese
Roberta Granese
Mpox is an emerging zoonotic infection caused by the Monkeypox virus, an Orthopoxvirus with increasing global relevance following the 2022 multinational outbreak. Historically endemic to Central and West Africa, the disease has evolved from sporadic zoonotic transmission to sustained human-to-human spread, particularly through close physical and intimate contact. Clinical manifestations typically include fever, lymphadenopathy, and progressive mucocutaneous lesions, although severity varies according to viral clade, immune status, and comorbidities. The 2022 outbreak, predominantly associated with the Clade IIb variant, was characterized by milder disease, localized lesions, and reduced mortality compared with the more virulent Clade I variant. Despite this, severe outcomes remain possible, particularly in vulnerable groups such as children, pregnant individuals, immunocompromised patients, and persons with extensive dermatological disorders. Diagnosis relies primarily on polymerase chain reaction testing from lesion-derived samples, with genomic sequencing serving as a complementary tool for epidemiological surveillance. Management is largely supportive, though antivirals such as tecovirimat may be considered in severe cases or in high-risk populations. Data regarding therapeutic safety in pregnancy are limited; however, tecovirimat appears to have the most favorable profile, whereas cidofovir and brincidofovir remain contraindicated. Prevention strategies include targeted vaccination with the non-replicating Modified Vaccinia Ankara–Bavarian Nordic vaccine, used for both pre- and post-exposure prophylaxis, particularly in individuals at elevated risk. Given the evolving epidemiological profile, the potential for vertical transmission, and the risk of adverse perinatal outcomes, Mpox infection during pregnancy poses unique clinical challenges. This review synthesizes current evidence on virology, clinical presentation, diagnosis, prevention, and management, with an emphasis on obstetric considerations and public health implications.

9 December 2025 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
RKRegis Kreitchmann
Regis Kreitchmann
Geraldo DuarteGeraldo Duarte
Geraldo Duarte
HMHelaine Milanez
Helaine Milanez
ATAna Gabriela Travassos
Ana Gabriela Travassos
ETEvelyn Traina
Evelyn Traina
MMMaria Luiza Bezerra Menezes
Maria Luiza Bezerra Menezes
Key points • Pregnancy is the period of greatest risk of infection by the human immunodeficiency virus (HIV) for women, and acute infection during pregnancy has a high potential for transmission of the virus to the baby. • Combined HIV prevention should be offered to women at risk, including use in pregnant and lactating women, in which Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) have proven safe. Pre-Exposure Prophylaxis should be started at least seven days before sexual exposure and can only be discontinued seven days after the last sexual intercourse. Adherence to PrEP (6 to 7 tablets per week) is essential to ensure efficacy in HIV prevention. • An HIV diagnosis allows access to antiretroviral therapy (ART) that can prevent sexual and perinatal transmission. The partner's prenatal care includes offering diagnostic tests to the partner and plays a fundamental role in preventing the woman from becoming infected. • The ART should be started as soon as possible during prenatal care to control viremia and minimize fetal and neonatal exposure to the virus. For women living with HIV (WLHIV), pregnancy represents a period of greater vulnerability to other infections, and the vaccination record should be reviewed and completed during prenatal care, including vaccinations against pneumococcus, influenza, COVID-19, and Tdap. • The mode of delivery should be defined according to maternal viremia levels in the third trimester. Most women with good adherence to ART will have a viral load (VL) lower than 1,000 copies/mL and may deliver vaginally. • Breastfeeding always represents a risk of postnatal transmission, and this must be communicated during prenatal care. The distribution of formula together with inhibition of lactation has been recommended by the Brazilian Ministry of Health and this option offers greater safety. Some countries have recently updated their guidelines in this area, including recommendations for counseling, information about risks and support when women wish to breastfeed, provided they have a history of undetectable VL, good adherence to ART and undergo frequent and careful follow-up. • Safe contraceptive methods, including LARCS (long-acting reversible contraceptives), should be offered to WLHIV for effective reproductive planning.